title: Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B.
authors.forename: R J
authors.initials: RJ
authors.lastname: Mayer
authors.forename: R B
authors.initials: RB
authors.lastname: Davis
authors.forename: C A
authors.initials: CA
authors.lastname: Schiffer
authors.forename: D T
authors.initials: DT
authors.lastname: Berg
authors.forename: E
authors.initials: E
authors.lastname: Sarno
authors.forename: E
authors.initials: E
authors.lastname: Frei
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage*; D003630:Daunorubicin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D003630:Daunorubicin